Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 13,827 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the sale, the general counsel now owns 160,437 shares in the company, valued at approximately $729,988.35. This trade represents a 7.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Benjamin Landry also recently made the following trade(s):
- On Monday, January 6th, Benjamin Landry sold 2,500 shares of Health Catalyst stock. The shares were sold at an average price of $7.52, for a total value of $18,800.00.
Health Catalyst Price Performance
Shares of NASDAQ HCAT opened at $3.97 on Tuesday. The business's 50 day moving average price is $5.67 and its two-hundred day moving average price is $7.14. The company has a market cap of $278.74 million, a PE ratio of -2.94 and a beta of 1.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a twelve month low of $3.76 and a twelve month high of $9.24.
Hedge Funds Weigh In On Health Catalyst
A number of institutional investors have recently bought and sold shares of HCAT. First Light Asset Management LLC grew its position in shares of Health Catalyst by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock valued at $37,055,000 after purchasing an additional 944,631 shares during the last quarter. Impax Asset Management Group plc grew its position in shares of Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after purchasing an additional 195,525 shares during the last quarter. Daventry Group LP grew its position in shares of Health Catalyst by 3.8% in the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company's stock valued at $17,742,000 after purchasing an additional 91,878 shares during the last quarter. Primecap Management Co. CA grew its position in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company's stock valued at $19,572,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its position in shares of Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after purchasing an additional 861,150 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.
Analysts Set New Price Targets
A number of analysts have recently commented on HCAT shares. Royal Bank of Canada cut their price target on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a report on Thursday, February 27th. Stephens lowered their target price on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Citigroup lowered their target price on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. KeyCorp raised Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 target price on the stock in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company lowered their target price on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $9.27.
Check Out Our Latest Stock Report on Health Catalyst
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
